Early Continuous Glucose Monitoring to Lower the Risk of Gestational Diabetes Mellitus in Women With Pre‐Pregnancy Obesity: Protocol for the Multicentre Randomised Controlled Trial (GLOW)

Yurong Lu, Zongyuan Tian, Jianhua Niu, Di Gao, Zhonghua Shi, Qiaoling Du, Yang Mi, Yunhui Gong, Jie Li, Jianying Yan, Hongwei Wei, Juan Juan, Huixia Yang
Diabetes, Obesity and Metabolism · Wiley · 2026-11-19 · DOI: 10.1111/dom.71563

Аннотация

ABSTRACT Aims Pre‐pregnancy obesity substantially increases the risk of gestational diabetes mellitus ( GDM ), yet preventive strategies before routine GDM screening remain limited. The Glucose monitoring to Lower risk of GDM in Obese pregnant Women ( GLOW ) trial aims to determine whether continuous glucose monitoring ( CGM ) initiated in early pregnancy reduces the incidence of GDM in women with pre‐pregnancy obesity. Materials and Methods GLOW is a national, multicentre, open‐label, parallel‐group randomised controlled trial enrolling 1034 women with pre‐pregnancy body mass index ≥ 28 kg/m 2 , a singleton pregnancy and gestational age ≤ 14 +6 weeks at eight hospitals in China. Participants will be randomised 1:1 to routine antenatal care alone or routine antenatal care plus CGM . In the CGM group, five consecutive 14‐day sensors will be used from 14 +0 –14 +6 to 24 +0 –24 +6 weeks of gestation (70 days in total), with access to glucose values and standardised CGM education. The primary endpoint is the incidence of GDM diagnosed by a 75‐g oral glucose tolerance test at 24 +0 –24 +6 weeks. Secondary outcomes include gestational weight gain, maternal metabolic and anthropometric measures, lifestyle behaviours and maternal and neonatal outcomes. Results and Conclusions GLOW will determine whether early CGM introduced before routine GDM screening can reduce GDM incidence and favourably influence maternal metabolic and pregnancy outcomes in women with pre‐pregnancy obesity. The findings may inform the role of early CGM as a preventive strategy in this high‐risk population. Trial Registration Chinese Clinical Trial Registry: ChiCTR2600130043

Читать у издателя →

Похожие статьи